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Abstract: The incidence of breast cancer continues to rise: 1.7 million women were diagnosed 
with and 521,000 women died from breast cancer in 2012. This review considers first current 
treatment options: surgery; radiotherapy; and systemic endocrine, anti-biological, and cytotoxic 
therapies. Clinical management includes prevention, early detection by screening, treatment 
with curative intent, management of chronic disease, and palliative control of advanced breast 
cancer. Next, the potential of novel drugs that target DNA repair, growth factor dependence, 
intracellular and intercellular signal transduction, and cell cycle are considered. Estrogen-related 
receptor alpha has attracted attention as a therapeutic target in triple-negative breast cancers 
with de novo resistance to, and in breast cancers with acquired resistance to, endocrine therapies 
such as antiestrogens and aromatase inhibitors. Estrogen-related receptor alpha is an orphan 
receptor and transcription factor. Its activity is regulated by coregulator proteins and posttrans-
lational modification. It is an energy sensor that controls adaptation to energy demand and may 
facilitate glycolytic metabolism and mitochondrial oxidative respiration in breast cancer cells. 
Estrogen-related receptor alpha increases breast cancer cell migration, proliferation, and tumor 
development. It is expressed at high levels in estrogen receptor-negative tumors, and is proposed 
to activate estrogen-responsive genes in endocrine-resistant tumors. The structures and functions 
of the ligand-binding domains of estrogen receptor alpha and estrogen-related receptor alpha, 
their ability to bind estrogens, phytoestrogens, and synthetic ligands, and the effects of ligand 
agonists, antagonists, and inverse agonists on biological activity, are evaluated. Synthetic ligands 
of estrogen-related receptor alpha have activity in preclinical models of metabolic disorders, 
diabetes, osteoporosis, and oncology. The clinical settings in which these novel drugs might 
have utility in the management of advanced breast cancer, and biomarkers for stratification of 
patients likely to benefit, are discussed. Finally, the potential side effects of the novel drugs on 
metabolism, osteoporosis, osteo-metastasis, and cachexia are considered.
Keywords: estrogen receptor alpha, inverse or reverse agonist, coactivators, ligand-binding 
domain, TFF1, HER2, antiestrogen-resistance
Introduction to breast cancer
incidence, mortality, and survival
Breast cancer is the most common cancer in women and the greatest cause of death 
from cancer in females. In 2012, 1.7 million women were diagnosed with breast cancer 
worldwide; men have a 100-fold lower risk of developing breast cancer than women. 
Across the world, over 522,000 women died as a direct result of their breast cancer 
(GLOBOCAN 2012 IACR).1
Breast cancer is considered very much a cancer of the western developed world; 
countries of Western Europe and North America, as well as Australia and New Zealand, 
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report the highest rates of new diagnoses (Figure 1A). The 
incidence is sevenfold higher in richer than in more deprived 
nations. The prevailing view is that lifestyle drives this higher 
rate of diagnosis; second-generation migrants from low-
incidence countries develop breast cancer with the incidence 
of their host nation. Belgium has the ignominious claim to the 
highest incidence; it has an age-standardized rate of diagnosis 
of over 110 cases per 100,000 women per annum (Figure 1B). 
Of the other 12 top countries, nine are Western European, but 
the Bahamas, Barbados, and the United States of America 
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Figure 1 worldwide incidence of breast cancer. 
Notes: Age-standardized incidence rates of breast cancer per 100,000 women throughout the world are shown; these measures remove any bias for different life expectancies 
in countries. The incidence of new diagnoses per 100,000 women per year (A). The mortality rates of breast cancer per 100,000 women per year throughout the world 
(C). The estimated numbers of women alive 5 years after being diagnosed with breast cancer per 100,000 women (E). Countries for which figures are unavailable are left 
uncolored. The incidences of new diagnoses (D) and mortality (M) per 100,000 women in the 12 countries with the highest (B) and lowest (D) incidences of diagnoses. The 
prevalence of women who have survived breast cancer for 5 years is shown in the six countries with the highest and six countries with the lowest incidence of diagnoses 
(F). Countries are indicated by their official ISO 3166-1 alpha-2 codes. Figures for male breast cancer are not available, but are between 0.5% and 1.0% of those shown for 
female patients. Data from GLOBOCAN 2012 (iARC).1 
Abbreviations: BB, Barbados; Be, Belgium; BS, Bahamas; BT, Bhutan; De, Germany; DK, Denmark; Fi, Finland; FR, France; GA, Gabon; GB, United Kingdom; GM, Gambia; 
GT, Guatemala; ie, Republic of ireland; iS, iceland; iT, italy; LS, Lesotho; MN, Mongolia; Mw, Malawi; MZ, Mozambique; NL, Netherlands; NP, Nepal; PG, Guinea; Rw, 
Rwanda; SZ, Swaziland; US, United States of America.
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also make the rank. The 12 lowest-incidence countries are 
mainly in sub-Saharan Africa, South Asia, and the Far East, 
and are all characterized by poverty.
The distribution of countries with the highest age-
 standardized mortality per 100,000 women throughout the 
world is very different (Figure 1C). Belgium has the highest 
mortality followed by the Republic of Ireland of the 12 coun-
tries with the highest rate of diagnosis, but they are outranked 
by poorer countries: Fiji, the Bahamas, Nigeria, and Pakistan. 
Mortality is relatively low in most of the lowest-incidence 
countries, but the likelihood that an individual will die from 
their breast cancer is much higher in low-incidence countries 
than in high-incidence countries (Figure 1B and D). For 
instance, a woman diagnosed with breast cancer in Belgium, 
the UK, France, or Iceland has an 82%, 82%, 84%, or 85% 
chance, respectively, of surviving her cancer and of dying 
of other causes. A woman diagnosed with breast cancer in 
Nepal, Mozambique, Papua New Guinea, or Comoros has 
only a 47%, 45%, 45%, or 44% chance, respectively, of 
surviving her disease. The reasons for the differential sur-
vival are multiple and include cultural influences, stage of 
presentation, and standards of health care.
Preferred sites of metastasis
Patients are unlikely to die of primary early breast cancer; the 
breast is a nonessential organ. Patients die from metastases 
to essential organs. Metastasis by localized spread is to the 
overlying skin and underlying muscles and ribs. Distant 
metastasis via the lymphatic drainage, vascular system, or 
neural network allows for the formation of secondary tumors 
in preferred organs notably bone, lung, liver, and brain.2 It is 
these secondary tumors that cause most of the terrible suf-
fering and pain associated with advanced breast cancer. The 
success of antibody therapies in some patients has resulted 
in an increase in deaths from brain metastases because the 
drugs that target, successfully the cancer cells throughout the 
rest of the body are unable to cross the blood–brain barrier 
and the malignant cells within the brain are able to thrive.3 
Intrathecal administration of the antibodies provides an 
attractive solution.4
Risk factors
The strongest risk factor for breast cancer is inheritance of 
an inactivating mutation in one of the familial breast cancer 
genes: BRCA1, BRCA2, CHEK2, p53, and ATM, which 
together contribute to around 5% of breast cancer cases.5 
The next highest risk factor is age: three-quarters of breast 
cancer cases present in postmenopausal women, less than 
5% in women less than 40 years of age and breast cancer is 
rare in women less than 30 years of age.5 Nevertheless, large 
numbers of premenopausal women develop breast cancer 
and it is the highest cause of death in women between 34 
and 54 years of age. Exposure to estrogens explains the 
majority of the other known risk factors for breast cancer. 
Early menarche, late menopause, nulliparity, absence of 
lactation, hormone replacement therapy, oral contraception, 
and treatment with the synthetic estrogen diethylstilbestrol 
are all associated with an increased risk of breast cancer. 
High circulating insulin-like growth factor-1 (IGF-1) and low 
serum insulin-like growth factor binding protein 3, as well as 
alcohol intake, are thought to increase risk, while exercise is 
thought to reduce risk.6–8
Obesity, the scourge of our times, is associated with a 
1.6-fold increased risk of breast cancer in postmenopausal 
women.6 Given the high basal incidence of postmenopausal 
breast cancer and the ongoing surge in obesity, predictions are 
that rates will rise at an alarming rate in the coming decades. 
The reasons why people with more body fat are more likely 
to develop breast cancer are debated, but it is incontrovertible 
that adipose cells express aromatase, which converts andro-
gens into estrogens, and 17β-hydroxysteroid dehydrogenase, 
which converts estrone into the more active 17β-estradiol. As 
adipose tissue accumulates in the body, local and circulat-
ing concentrations of estrone and 17β-estradiol increase.6 
Exposure to high local and circulating concentrations of IGFs 
secreted by adipose tissue may contribute to the increased 
risk of breast cancer in obese individuals.6,9,10 In addition, 
high concentrations of circulating insulin in obese individu-
als who develop hyperinsulinemia and metabolic syndrome 
may contribute.6
Recent rise
A recent study reported a huge rise in presentation of young 
women with advanced, estrogen receptor-positive breast 
cancer.11 Rates of presentation had risen 2% per year for 
women less than 40 years of age and 3% per year for women 
less than 34 years of age. No explanation was proffered for 
the increases observed, but they are cause for alarm and may 
be related to changes in lifestyle factors such as obesity.
Brief overview of current treatment 
options and emerging therapies
Efforts to counteract or lessen the impact of breast cancer 
can be divided into five main phases: the “holy grail” of 
prevention, earlier detection, cure, management as a chronic 
disease, and palliation of symptoms (Figure 2).
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Figure 2 Treatment options for prevention, early detection, and clinical management of patients diagnosed with breast cancer.
Notes: Possible means by which breast cancer might be reduced in women at low and high risk of developing breast cancer (A) and possible approaches with which to detect 
the presence of asymptomatic breast cancer in low- and high-risk populations (B). Options for treatment of premenopausal and postmenopausal patients who present with 
early, localized breast cancer (C). Options for clinical management of women with chronic breast cancer (D) or with disseminated, advanced breast cancer (E). The dark 
pink dots provide a graphical representation of the presence, size, and extent of demonstrable disease. 
Abbreviations: CT, computed tomography; GP, general practitioner; MRi, magnetic resonance imaging.
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Prevention
Prevention of any cancer is the ultimate aim (Figure 2A). For 
individuals who have an inherited predisposition to develop 
breast cancer because they have inherited a mutated copy 
of one of the susceptibility genes, radical intervention is 
appropriate. Surgical removal of the susceptible breast tissue 
at an early age is one option. Alternatively, individuals may 
receive long-term systemic therapy with antiestrogens, an 
aromatase inhibitor, aspirin, bisphosphonates, or metformin, 
all of which have proven ability to reduce the development 
of breast cancer in these women.12,13
For others, education to alter lifestyle choices that pre-
dispose towards cancer is paramount. Reduction in obesity 
could have a huge impact on the number of people who will 
develop breast cancer. Reduction in, restricted duration of, 
or altered composition of medications such as oral contra-
ceptives and hormone replacement therapy to reduce the 
length of time that breast tissue is exposed to estrogens and 
the concentration of estrogens to which it is exposed has the 
potential to reduce the incidence of breast cancer. General 
physical and mental well-being, exercise, and reduced alcohol 
intake may reduce risk.7,8,14
early detection
If breast cancer cannot be prevented, the next most effective 
strategy is early detection; the rationale being that a cancer 
detected early is a curable cancer. Screening is most cost 
effective in individuals at high risk of developing cancer 
(Figure 2B). Women in the Western world who have inherited 
a mutated copy of one of the genes that predisposes to breast 
cancer are offered annual magnetic resonance imaging from 
an early age. Magnetic resonance imaging is more effective 
than mammography in younger breast tissue. Breast tissue 
in younger women tends to be denser than breast tissue 
in older women, because breast tissue in older women is 
more likely to contain a higher proportion of adipose tissue. 
Dense breast tissue is visible on a mammogram and difficult 
to distinguish from a breast cancer. Women in the Western 
world who have been exposed to high levels of therapeutic 
or industrial radiation are also screened from an early age. It 
is debatable whether clinically obese individuals should be 
screened earlier than the general population.
In the low-risk population, younger women tend to rely on 
self-awareness and self-examination, which are of question-
able benefit. Older women are often offered mammographic 
screening. Three-yearly screening is offered now as standard in 
the UK for women between 47 and 73 years; in New  Zealand 
for women between 45 and 69 years, and, in  Denmark for 
women between 50 and 69 years of age.  Detection of a 
potential abnormality is followed by triple assessment: further 
mammographic or ultrasound imaging; clinical examination; 
and cytological or histological examination of a fine-needle 
aspirate, core biopsy, or vacuum-assisted mammotome biopsy. 
The benefits of universal breast screening remain controver-
sial.15,16 Some argue that more women should be screened, 
while others contend that the lives saved are at an unaccept-
able human and financial cost. Current estimates suggest that 
a cancer will be detected in 6.81%, a life saved in 0.43%, and 
a cancer detected and treated that never would have caused 
any morbidity in 1.29% of women screened.16 Baum contends 
that the benefit of universal screening in terms of reduction in 
death from breast cancer is outweighed by cardiopulmonary 
and other adverse effects of treatment.17 Others argue that for 
fit, healthy, slim women, the risk of radiation outweighs the 
benefits of potential early detection.18
Treatment of early breast cancer
Breast cancers that are detected early may be treated with 
curative intent (Figure 2C). Research in the 1980s con-
firmed that wide local excision accompanied by appropriate 
lymph node clearance was as effective as a simple or radical 
 mastectomy.19,20 More recently, detection of and histological 
evaluation of the sentinel node has reduced the number of 
patients who undergo unnecessary lymph node clearance with 
associated resultant debilitating lymphedema and neuropathic 
pain. As a result, surgeons now cure breast cancer with much 
lower associated morbidity than previously.
In contrast to many other major solid tumors, such as lung, 
gastric, or pancreatic adenocarcinomas, patients with breast 
cancer often relapse with disseminated disease over 10 years 
after their initial diagnosis. For this reason, and because of 
its proven benefit, almost all women diagnosed with early 
breast cancer will be offered some form of adjuvant therapy, 
which is therapy given after surgical resection in the absence 
of demonstrable residual disease. Adjuvant therapy may be 
radiotherapy to the breast and axilla or systemic cytotoxic, 
endocrine, or anti-human epidermal growth factor receptor 2 
(HER2) therapy. Interestingly, obese patients or patients 
who gain weight during adjuvant therapy are less likely to 
benefit.21 A disadvantage of adjuvant treatment is that it is 
not known which patients will or will not benefit from their 
treatment because they do not have measurable disease. 
A consequence is that outwith clinical trials, patients who 
experience severe side effects from their drugs when they do 
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not feel ill from their potential occult disease are less likely 
to comply. It is estimated that over 40% of women prescribed 
adjuvant endocrine therapy outside of clinical trials do not 
comply.22,23 There is a clear need to develop strategies with 
which to identify women who do require and who will benefit 
from different adjuvant therapies.
Management of chronic breast cancer
The combination of early detection, improved clinical man-
agement, and general increased longevity has resulted in there 
being over 6,250,000 survivors of breast cancer worldwide 
whose breast cancer was diagnosed within the past 5 years 
(GLOBOCAN, 2012;1 Figure 1E). The worldwide distribu-
tions of age-standardized incidence of diagnoses and of 
prevalence of breast cancer survivors are similar, because 
countries with high rates of diagnosis tend to have better 
survival and countries with low rates of diagnosis tend to 
have worse survival (Figure 1B, D and F). Many of these 
breast cancer survivors will die from diseases other than their 
breast cancer and can be considered to have chronic breast 
cancer. Many will receive adjuvant radiotherapy or systemic 
cytotoxic, endocrine, or anti-HER2 adjuvant therapy (Figure 
2D). Other strategies include bisphosphonates, zoledronic 
acid, or alendronic acid, to strengthen the bones and reduce 
the formation of osteo-metastases. Some will receive adju-
vant endocrine therapy for 10 years.24 These patients require 
long-term surveillance, which may include computed tomog-
raphy scans. Some will relapse and will benefit from multiple 
successive interventions designed to keep their disease at 
bay. Patients who relapse during adjuvant therapy will have 
developed disease that is resistant to the drugs that they took 
during their adjuvant therapy. A goal for the pharmaceutical 
industry is to develop strategies and new drugs to reduce or 
delay the onset of resistance and for the medical oncologist 
to keep one step ahead of the evolving disease. Patients with 
significant comorbidities or advanced disease may be offered 
primary endocrine therapy. Some of these women will benefit 
from this systemic therapy for the remainder of their lives, 
but others will relapse with resistant disease and require 
alternative intervention or palliative care.
Treatment of advanced breast cancer
For patients who present with advanced disease or who relapse 
with advanced disease, therapy will be largely palliative 
 (Figure 2E). Patients present with advanced disease for dif-
ferent reasons: they may have particularly aggressive disease; 
there may be cultural taboos; or they may live in a country 
with inadequate health care or be too poor to seek help. 
 Neoadjuvant therapy may be necessary to downsize the 
 primary tumor prior to surgery. Palliative treatment will aim to 
reduce tumor burden and slow the progression of the  disease. 
Strategies can include surgery, radiotherapy, cytotoxic or 
anti-biological therapies, and pain management.
Current systemic therapies
Systemic therapy has important roles in breast cancer man-
agement to treat advanced disease, to treat frail patients, as 
adjuvant therapy for early operable disease, and as neoadju-
vant therapy to downsize inoperable tumors or to downsize 
operable tumors and enable breast conservation. Therapy 
decisions are based upon the age of and menopausal status 
of the patient; existence of comorbidities; clinical stage; 
prognostic indicators such as tumor size, histological grade, 
and axillary lymph node involvement; and the expression 
of the estrogen and progesterone receptors and HER2 in the 
primary tumor cells.
All four of the major classes of cytotoxic drug have a 
role. Therapy will usually include a topoisomerase inhibitor, 
doxorubicin or epirubicin, combined with the antimetabolite 
5-fluorouracil and the alkylating agent cyclophosphamide. 
A taxane to disrupt microtubule formation, docetaxel, may 
be given in combination or sequentially to the former drugs 
and has utility in treatment of anthracycline-resistant disease. 
Capecitabine, an alternative antimetabolite, is often given as 
second-line therapy and the alternative antimicrotubule agent 
vinorelbine as third-line therapy. Platinum complexes such 
as carboplatin or cisplatin may be active.
Patients whose tumor cells express estrogen or progesterone 
receptor are eligible for endocrine therapy. Endocrine therapy 
prevents ovarian synthesis of estrogens either with the luteinis-
ing hormone-releasing hormone (LHRH) analog goserelin in 
premenopausal women or by oophorectomy in pre- or peri-
menopausal women. Conversion of androgens into estrogens 
may be inhibited with aromatase inhibitors such as letrozole, 
anastrozole, or exemestane in postmenopausal women. Alter-
natively, the interaction between estrogens and their nuclear 
receptor may be inhibited with antiestrogens such as tamoxifen, 
raloxifene, or fulvestrant in all breast cancer patients.
Tumor cell expression of membrane-bound HER2 or 
amplification of the HER2 gene constitutes eligibility for 
anti-HER2 therapies. The antibodies trastuzumab and pertu-
zumab inhibit dimerization of HER2 with other members of 
its receptor family. Small molecule inhibitors of the activation 
by phosphorylation of HER2, such as lapatinib, may be used 
in combination with trastuzumab or in patients who develop 
trastuzumab-resistant disease. Recently, ado-trastuzumab 
emtansine (T-DM1), a drug in which trastuzumab is con-
jugated to the cytotoxin mertansine, has been approved for 
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treatment of advanced breast cancer patients whose disease 
has progressed after treatment with trastuzumab.25,26
emerging systemic therapies
Enormous effort has been expended to develop drugs against 
novel targets and many have been evaluated in clinical trials, 
either as single agents or in combination with established 
regimens. Among the most popular are agents that potentiate 
the DNA damage induced by cytotoxic drugs or mutations 
in genes that encode enzymes in the DNA damage response 
of malignant cells.27 Cytotoxic drugs cause substitution with 
nucleotide analogs, which is reversed by base excision repair; 
formation of DNA adducts, that are removed by nucleotide 
excision repair; DNA double-strand breaks that are repaired 
by nonhomologous end-joining; stalled replication forks due 
to single-strand breaks which are restored by homologous 
recombination; or interstrand crosslinks that are excised by 
interstrand crosslink repair. The rationale behind the devel-
opment of drugs that inhibit DNA repair is that DNA repair 
antagonizes cytotoxic drugs and that inhibition of DNA 
repair enzymes will potentiate the drugs. Agents that inhibit 
DNA-dependent protein kinase are designed to potentiate 
drugs that induce DNA double-strand breaks and interstrand 
crosslinks. Inhibitors of poly(adenosine diphosphate-ribose) 
polymerase prevent single-strand repair and therefore induce 
double-strand breaks and subsequent cell death in cells in 
which enzymes such as BRCA1, BRCA2, or ATM (ataxia 
telangiectasia mutated) are defective.27
Other agents are designed to prevent the dependence of 
malignant cells on diverse growth factors and their  receptors. 
At the forefront are agents that target members of the human 
epidermal growth factor receptor family (HER): epidermal 
growth factor receptor (EGFR), HER2, HER3 and HER4.28–30 
The dependence of many tumor cells on the IGFs31–34 led 
to the development of drugs that sequester the ligands or 
inhibit their receptors.6,35 The fibroblast growth factor recep-
tor has received attention. The potency of the agents is low, 
but promising results have been obtained in patients with 
amplified FGFR1 analogous to the treatment of patients with 
amplified HER2.36 Inhibitors of the scatter factor receptor 
MET are being considered.
Substantial effort has focused on two main intracellular 
signal-transduction pathways: PI3K–Akt–mTor37 and Ras–
Raf–MAPK.38 Many specific or pan-PI3K inhibitors have 
entered clinical trials, as have inhibitors of Akt, mTor1, and 
mTor2.39 Mutations of Ras and Raf are relatively infrequent 
in breast cancer and their inhibitors have received less atten-
tion than in other cancers, but MEK inhibitors have shown 
some success.40 Given the ubiquitous importance of these 
signal-transduction molecules in the response of all cells to 
many different extracellular signals, it is questionable whether 
these agents will have sufficient specificity.  Alternatively, the 
possibility that some breast cancers are dependent on other 
steroid hormones has led investigators to test antiandrogens 
such as bicalutamide and enzalutamide.41
Drugs have been developed to target cyclins and cyclin-
dependent kinases but tend to lack tumor cell specificity.42  
Recent interest has investigated specific characteristics of 
cancer stem cells,43 the rationale being that elimination of 
such cells is central to the destruction of the tumor because 
they control cell renewal and resistance to therapy. Interest 
prevails in strategies that encompass the interactions between 
the malignant cells and their microenvironment. For instance, 
drugs that target chemokines such as CXCL12 and its recep-
tor CXCR4 have been investigated.44 There is considerable 
interest in the potential to target the interactions between 
cells via, for instance, β-catenin, or with the extracellular 
matrix via integrins, or the consequence of integrin signal 
transduction.45 Another strategy is to potentiate and extend 
tumor hypoxia.46
Introduction to the estrogen-
related receptor alpha
estrogens
Steroid hormones are small hydrophobic molecules that 
are transported in the blood bound to sex hormone binding 
globulin and are able to diffuse in and out of cells. Estrogen 
target tissues include breast, endometrium, bone, brain, 
liver, and heart. Derived from cholesterol, estrogens share a 
common four-ring structure and have important roles in sex 
determination, fertility, pregnancy, immune response, bone 
formation, and in the cardiovascular system. Cholesterol is 
converted into progestins, then into androgens and, finally, 
estrogens in a series of enzymatic reactions.6 Synthesized 
predominantly in the ovaries in premenopausal women, the 
principal site of estrogen synthesis in older women and in 
men is in peripheral tissues, notably adipose tissue.6
There are three estrogens, which are named for the num-
ber of hydroxyl groups: estrone, estradiol, and estriol. Estrone 
and estradiol are produced by aromatization of androstene-
dione and testosterone, respectively. Estriol is synthesized in 
the liver and placenta. Estriol is considered the major estrogen 
in pregnant women, estradiol in premenopausal women, 
and estrone in postmenopausal women. Concentrations of 
estrone and estradiol increase with obesity in postmenopausal 
women and in men.6,9 The surge in estrogen concentrations at 
puberty contributes to the development of secondary sexual 
characteristics including the female breast. Cyclical changes 
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in concentration during the menstrual cycle cause cyclical 
changes in breast size and tenderness. Reduction in estrogen 
concentrations on cessation of lactation or menopause lead 
to breast involution.
The role of the estrogen receptor
The existence of a high-affinity receptor for estrogen was 
recognized initially by Jensen.47 Each steroid hormone fam-
ily has its own protein receptor. These receptors are found in 
the steroid target cells and are ligand-dependent transcription 
factors, inactive until bound by their ligand (Figure 3A). The 
activated transcription factors coordinate formation of com-
plexes of coactivator or corepressor proteins on the chromatin 
of their target genes. The composition of the transcription 
complexes, which depends on the receptor, the availability 
of coactivator and corepressor proteins, and on the DNA that 
surrounds the interaction site in the responsive gene, deter-
mines whether transcription is activated or repressed. 
The estrogen receptor is a 66 kDa protein of 595 amino 
acid residues sequestered in estrogen target cells in its inac-
tive form in a complex with proteins including heat shock 
proteins 70 and 90, cyclophilin 40, FKBP51, and FKBP52 
(Figure 3A). Estrogens diffuse into the target cells and bind 
with high affinity to their receptor, which dissociates from 
its sequestered complex. Estradiol has the highest affin-
ity for the estrogen receptor, followed by estriol and then 
estrone.48 Interaction with the ligand leads to dimerization 
of the receptor and stabilizes a conformation that creates a 
surface on the receptor with which transcriptional coregula-
tors interact. The dimeric receptor binds to estrogen response 
elements (EREs) in the promoters of estrogen-responsive 
genes.49,50 Coactivators, for instance, members of the p160 
steroid receptor coactivator (SRC) family (SRC-1, SRC-2, 
and SRC-3), bind through one of three LXXLL motifs that 
form amphipathic alpha-helices.51,52 The p160 SRC proteins 
interact, in turn, with the histone acetyltransferases, cyclic 
adenosine monophosphate (cAMP) response element-
binding protein (CREB)-binding protein (CBP), and p300, 
which acetylate, and with coactivator-associated arginine 
methyltransferase 1 (CARM1) and protein arginine N-meth-
yltransferase 1 (PRMT1), which methylate, histones within 
the nucleosomes. An RNA helicase A (RHA), and an ATP-
dependent chromatin remodeling complex, SWItch/Sucrose 
NonFermentable (SW1/SNF), are recruited. The resultant 
coactivator complex modifies the nucleosomes and alters 
the surrounding chromatin to allow access to the activating 
transcription factor proteins, TATA-binding protein, and RNA 
polymerase II machinery, and transcription ensues. Posttrans-
lational modifications may affect the  activity of the estrogen 
receptor.52,53  Alternatively, corepressors, such as ligand-
dependent corepressor (LCoR) and receptor-interacting 
protein 140 (RIP140), are recruited and attract deacetylases 
and demethylases to inhibit transcription.
Domain organization of estrogen 
receptors
Nuclear steroid receptors comprise five separate domains 
(Figure 4A). From the amino-terminus, the hormone-
 independent transcription activation domain comprises 
also a nuclear localization signal. It is followed by the 
DNA-binding domain, which contains a second nuclear 
localization signal. The DNA-binding domain is separated 
by a short hinge region from the ligand-binding domain, 
which is the largest domain and contains a dimerization 
domain and a transcription repression domain. The second 
transcription activator domain, which is ligand dependent, 
is at the carboxy- terminus. There are two estrogen receptors. 
The first, cloned in 1985 from estrogen-responsive breast 
cancer cells,54,55 is expressed in classic estrogen target cells 
and tissues and is responsible for the standard estrogen 
responses listed above. It is this receptor that is measured 
as an important prognostic and predictive biomarker in 
hormone-dependent breast cancer. The second, which is a 
59.2 kDa receptor of 530 amino acids, identified in 1996,56 
was called estrogen receptor beta; the former was renamed 
estrogen receptor alpha at this time to distinguish between the 
two. Estrogen receptor beta is reported to be expressed more 
widely than oestrogen receptor alpha and its function is less 
well understood. Conservation between the two paralogs is 
variable: low in the domains that interact with transcription 
activators and in the hinge region, at 25-30%; intermediate 
in the ligand-binding domain, at 60%; and highest, at 90%, 
in the DNA-binding domain (Figure 4C).
estrogen-related receptor alpha
In 1988, 8 years before discovery of estrogen receptor beta, 
two other members of the estrogen receptor family were 
discovered by Giguère et al:57 a 45.5 kDa, 423 amino acid 
residue protein named estrogen-related receptor alpha; and a 
56.2 kDa, 508 amino acid residue protein named estrogen-re-
lated receptor beta. Later, the estrogen-related receptor gamma 
of 51.3 kDa, 458 amino acid residue protein was identified.58 
Evolutionarily, estrogen-related receptor beta and gamma are 
closer to each other than to estrogen-related receptor alpha 
(Figure 4B). Comparison of the primary sequences in the dif-
ferent receptor domains shows relatively strong conservation 
of around 65% in the DNA-binding domains and less, around 
35%, in the ligand-binding domains.  Conservation is lower 
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Figure 3 Mechanisms of activation of estrogen receptor alpha and estrogen-related receptor alpha.  
Notes: (A) estrogen-responsive cells harbor the estrogen receptor alpha (pale pink), which is a ligand-dependent transcription factor inactive in the absence of ligands. 
estrogens: estrone (e1), estradiol (e2), and estriol (e3) are synthesized in the ovaries, in peripheral tissue, or in the placenta and transported in the blood bound to sex hormone-
binding globulin (pale blue-gray). Estrogens diffuse through the cellular plasma and nuclear membranes and bind with high affinity to the estrogen receptor. This interaction 
leads to dissociation of chaperone proteins (pale green), including heat shock protein 90 (90), heat shock protein 70 (70), and cyclophilin 40 (40), from the receptor, which 
undergoes conformational structural changes and dimerization. The dimerized estrogen receptor ligand complex interacts with specific estrogen response elements (EREs) 
in the DNA of its responsive genes such as TFF1. interaction with coregulator proteins (pale blue) via the coactivator recruitment surface brings these coregulators into 
the vicinity of the promoters of the responsive genes. Coactivator proteins interact in turn with proteins, such as histone acetyltransferases or methyltransferases (cyan-
blue), that acetylate or methylate the histones to induce local chromatin decondensation and increased accessibility to the promoter elements for the RNA polymerase ii 
initiation complex (yellow); transcription of the responsive genes ensues. TFF1 mRNA is translated and the protein secreted from the target cells to exert its effects, which 
are thought to include cell migration on its target cells.66 Alternatively, the receptor interacts with corepressors, and the transcription of other responsive genes is ablated. 
The estrogen response may be inhibited by prevention of estrogen synthesis with aromatase inhibitors or by competitive inhibition of the interaction of the ligand with 
the receptor in target cells. (B) The estrogen-related receptor alpha (pink) is present in responsive cells. Being an orphan receptor, its activity is not thought to require 
the presence of a ligand. instead, the activity is thought to depend upon the availability of coactivator proteins such as peroxisome proliferator-activated receptor-gamma 
coactivator (PGC)-1α or PGC-1β (pale blue) or corepressor proteins. induction of the expression of these proteins in response to metabolic stress or starvation allows the 
estrogen-related receptor alpha to function as a transcription factor and induce or repress the expression of its responsive genes. The dimerized estrogen-related receptor 
alpha complex interacts with specific response elements (ERREs) in the DNA of its responsive genes such as TFF1. The activity of estrogen-related receptor alpha is affected 
also by phosphorylation (gold) in response to stimuli through the insulin-like growth factor or epidermal growth factor cell surface receptors (pink and green, respectively). 
The activity of estrogen-related receptor alpha may be inhibited by cessation of synthesis of the receptor or of its activator proteins. inhibitors of epidermal growth factor or 
insulin-like growth factor signal transduction may also have utility in responsive cells. Alternatively, inverse agonists prevent its interaction with the coregulators. The activity 
of estrogen-related receptor alpha may be enhanced by ligands that increase its affinity for the coactivators, possibly by stabilizing the receptor in its active conformation.
Abbreviations: Ac, acetylation; Me, methylation; eRα, estrogen receptor alpha; eRRα, estrogen-related receptor alpha; mRNA, messenger RNA; Pol, RNA polymerase ii.
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outwith these domains, and the estrogen-related receptors 
alpha and gamma lack an F domain (Figure 4C).
The estrogen-related receptor alpha interacts with coregu-
lator proteins and binds to specific DNA sequences of its target 
gene promoters, primarily as a homodimer (Figure 3B). The 
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Figure 4 Generic nuclear receptor structure, and estrogen receptor family phylogeny and shared homologies. 
Notes: Steroid hormone receptors share a conserved five-domain structure (A): domain A/B, which is involved in transcription activation and nuclear localization; domain 
C, which is the DBD; domain D, which serves as a hinge between the DBD and LBD; domain e, which is the LBD, responsible also for dimerization, transcription activation, 
and transcription repression; and domain F, which contains part of the second transcription activation domain. Phylogenetic analysis indicates that the genes that encode the 
five estrogen receptor proteins have evolved from a common precursor gene (B). The estrogen-related receptor alpha is the most distant. The percentage conservation 
between the estrogen receptor alpha (yellow text) and the other four proteins, and between the estrogen-related receptor alpha (white text) and the other four proteins, 
is shown for each of the five domains (C).
Abbreviations: NLS, nuclear localization signal; AF1, hormone-independent transcription activation domain; DBD, DNA-binding domain; HR, hinge region; LBD, ligand-
binding domain; DD, dimerization domain; AR, transcription repression domain; AF2, hormone-dependent transcription activation domain.
peroxisome proliferator-activated receptor (PPAR) gamma 
coactivator (PGC)-1 family (PGC-1α, PGC-1β, and PPRC-1) 
and the p160 SRC proteins interact with this estrogen-related 
receptor alpha coactivator surface via LXXLL motifs.51 The 
most notable difference between estrogen-related  receptors 
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and estrogen receptors is that the former function as 
 aporeceptors when they are not bound to ligand.
estrogen receptor family  
DNA-binding domains
Arguably the domain most central to the specific functions of 
the estrogen receptor family is the conserved DNA-binding 
domain that recognizes sequences in the responsive genes 
and dictates with which genes the receptor will interact. This 
relatively short sequence of 70 amino acid residues contains 
two zinc-binding elements. In each, a zinc ion is ligated tet-
rahedrally by four cysteine residues (Figure 5). This class II 
zinc-binding motif comprises, from the amino-terminus, 
a zinc finger, an alpha helix, the second zinc finger, and the 
second alpha helix. The first alpha helix is the recognition 
helix that fits into the major groove of the double-stranded 
DNA. The structure of the estrogen receptor alpha DNA-
binding domain in complex with DNA illustrates that the 
receptor dimer locates primarily on one face of the DNA 
helix (Figure 5C).59 The side chains of the residues make 
specific contacts with four DNA bases. The three residues 
responsible for the DNA interface are referred to sometimes 
as the proximal box. One of these residues, alanine in the 
estrogen-related receptors, is a glycine in the two estrogen 
receptors. The second region of intermolecular interaction is 
responsible for the dimerization interface and is referred to 
sometimes as the distal box. This region contains uniquely 
in estrogen-related receptor alpha a single conservative 
 substitution of a serine in place of a threonine.
Members of the estrogen receptor family bind to specific 
conserved DNA recognition sequences in the DNA of their 
responsive genes (Figure 6). Often, but not always, located 
proximal to the promoters, they may be up to 100 kb from 
the promoter of the responsive gene. The canonical estro-
gen response element or ERE 5′-AGGTCA-3′ is followed 
by three bases of indeterminate sequence and then by the 
inverse sequence 5′-TGACCT-3′.60–64 The palindromic nature 
of the perfect ERE is predictable given the perfect dimeric 
structure formed by interaction of the two receptor DNA-
binding domains (Figure 5C). Reduction in the length of the 
palindromic sequence by a base on either side reduces the 
affinity of the interaction with the receptor dimer. The third 
base pair of the ERE half-site, G–C, provides binding energy, 
and the fourth base pair, T–A, makes a positive contact with 
the receptor. Most EREs identified differ from the canonical 
sequence by at least one base pair.63
The estrogen-related receptor alpha affects the transcrip-
tion of known estrogen-responsive genes, such as those that 
encode lactoferrin, osteopontin, thyroid receptor alpha, 
aromatase (CYP19), and TFF165,66 via interaction with the 
EREs in these genes.67–71 Detailed analysis suggests that 
estrogen-related receptor alpha binds particularly well if the 
sequence is preceded by 5′-TAA-3′ or 5′-TCA-3′, and it is 
suggested that the estrogen-related receptor alpha response 
element (ERRE) is 5′-TA/CA AGGTCA-3′. The presence 
of a combined ERRE and ERE will ensure regulation of a 
gene by both receptors. It is noteworthy that the TFF1 pro-
moter contains an imperfect ERRE and an imperfect ERE 
(Figure 6).
estrogen receptor family  
ligand-binding domains
The ligand-binding domains of the estrogen receptor fam-
ily are composed almost entirely of 12 helices, of which 
eleven are arranged in three antiparallel layers.72 Helices 5, 
6, 9, and 10 comprise the central core layer,which is sand-
wiched between helices 1–4 on one face and helices 7, 8, 
and 11 on the other (Figure 7A). In the estrogen receptors, 
this wedge-shaped molecular scaffold creates a sizeable 
hydrophobic cavity at its narrower end into which estrogens 
slip and interact with high affinity. The remaining secondary 
structural elements, a small two-stranded antiparallel β-sheet 
and helix 12, flank the main three-layered motif on either 
side of the hydrophobic pocket (Figure 7A). After interac-
tion with estrogens, helix 12 is positioned as a lid over the 
ligand-binding pocket to secure the ligand in position and 
posit the hydrophobic side chains of helix 12 toward the 
steroid (Figure 7B).72 This conformation creates a surface on 
the receptor that includes the charged residues, Lys362 at the 
end of helix 3 and Asp538, Glu542, and Asp545 from helix 
12, that were identified by mutation analysis to be important 
for transcription activation (Figure 7A).73  Subsequent analysis 
of the structure of the ligand-binding domain of estrogen 
 receptor alpha bound to the synthetic estrogen diethylstil-
bestrol and a coactivator peptide with an LXXLL motif 
identified more fully the coactivator recruitment surface.74 
The interaction surface comprises a hydrophobic cleft formed 
with residues from helices 3, 4, 5, and 12 and the turn between 
helices 3 and 4 (Figure 7C). Interaction of the amphipathic 
alpha-helical coactivator peptide buries approximately 
1,000 Å2 of the hydrophobic interaction  surface. The majority 
of the residues involved in the interaction are hydrophobic. 
In addition, the main chain conformation of the coactivator 
peptide is stabilized by charged capping interactions at either 
end of the peptide helix with Lys362 from helix 3 and Glu542 
from helix 12 of the receptor (Figure 7C).
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Figure 5 DNA-binding domains of the estrogen receptors.
Notes: The primary sequences of the DNA-binding domains of the five estrogen receptors are aligned (A). vertical lines indicate amino acid residues that are identical 
in estrogen receptor alpha and beta, or in the three estrogen-related receptors, and dots indicate conserved substitution of residues. Residues that are identical in all five 
proteins are indicated by a small circle, and those that are substituted conservatively by a dot underneath the sequences. Cysteine residues are colored ochre and are in bold. 
The residues in the proximal box (P-box) that are responsible for interaction with DNA and those in the distal box (D-box) that are involved in the dimerization interface 
are in bold and are underlined. The two residues that are unique to estrogen-related receptor alpha are colored red. A small gold sphere is above the four cysteine residues 
that bind tetrahedrally to one zinc ion and a small blue sphere is above the cysteine residues that bind tetrahedrally to the second zinc ion. Regions of secondary structure 
are indicated below the sequences: turn (gray arrow), beta strand (yellow arrow), and alpha helix (pink cylinder). The estrogen-related receptor alpha DNA-binding class ii 
zinc-binding motif is illustrated graphically (B) and a ribbon representation of the structure of the of the estrogen receptor alpha in complex with DNA is shown (C) with 
the same conventions as in (A).
After interaction of antiestrogens such as the active metab-
olite of tamoxifen, 4-hydroxytamoxifen, or raloxifene with 
the ligand-binding domain of estrogen receptor alpha, a por-
tion of the ligand remains outside the ligand-binding pocket 
(Figure 7A).72,74 The extruded ligand prevents alignment of 
helix 12 over the ligand-binding pocket and hence formation 
of a complete coactivator recruitment surface. Instead, helix 
12 is positioned over the hydrophobic cleft between helices 3, 
4, and 5, in which position it precludes completely interaction 
of coactivators with this surface of the receptor.
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Estrogen receptor alpha
Vitellogenin A2 ERE 5'-GTCAGGTCACAGTGACCTGAT - 3'
Progesterone receptor B ERE 5'-AAGGGCAGG AGCTGAC
AC
CAGCG- 3'
Progesterone receptor A ERE 5'-GCGAGGTCACCA GCTCTTGGT- 3'
Cathepsin D element 2 ERE 5'-GCTGGGCCGGGCTG CCCGC- 3'
TFF1 ERE 5'-GCAAGGTCAGCGTGGCCAC- 3'
Canonical ERE 5'-AGGTCAnnnTGACCT- 3 ' 
Estrogen-related receptor alpha 
Lactoferrin ERRE 5'- TCAAGGTCATC-3'
Osteopontin 1 ERRE 5'- TAAAGGTCA-3'
Osteopontin 2 ERRE 5'- TCAGGGTCA-3'
Thyroid receptor alpha ERRE 5'- TCAAGGTCA-3'
Aromatase ERRE 5 ' - - - AAGGTCAGAAT-3'
TFF1 1 ERRE 5'-              TTAAGGTCAGG-3'
TFF1 2 ERRE  5'- TGCAGGTCAGC-3'
Canonical ERREs 5'- TCAAGGTCA-3'
5'- TAAAGGTCA-3'
Both receptors
TFF1 ERRE and ERE 5'-TGCAAGGTCAGCGTGGCCAC-3'
Canonical ERRE and ERE 5'-TCAAGGTCA n n nTGACCT-3' 
A
B
C
 PGC-1α PGC-1α
p160 p160   PGC-1α PGC-1α
Figure 6 DNA response elements recognized by estrogen receptor alpha and estrogen-related receptor alpha.
Notes: The sequences of the EREs identified in key estrogen responsive genes are aligned above the consensus perfect palindromic sequence (A). The sequences of the 
ERREs identified in its responsive genes are aligned above the canonical sequence (B). The dual eRRe and eRe found in the promoter region of the TFF1 gene is shown above 
a perfect combined eRRe and eRe (C). The important third and fourth base pairs of the eRe or eRRe half-sites that provide binding energy and make positive contact with 
the receptor, respectively, are underlined when they are the conserved canonical sequence in the response elements.
Abbreviations: eRe, estrogen response element; eRRe, estrogen-related receptor alpha response element.
The secondary and tertiary structures of the ligand-
 binding domains of estrogen-related receptors are extremely 
similar to those of the estrogen receptors, but subtle differ-
ences are proposed to allow them to function as aporecep-
tors and explain the failure to identify their natural ligands. 
Notably, in the structure of the estrogen-related aporeceptor 
alpha, helix 12 is positioned across the ligand-binding domain 
(Figure 7A).75 Thus the four charged residues, Lys244 in helix 
3 and Lys412, Glu416, and Glu419 in helix 12, equivalent 
to those thought originally to be critical for activation of 
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transcription in estrogen receptor alpha, are on the same face 
of the receptor in the absence of ligand. The crystal structure 
of estrogen-related receptor alpha includes the coactiva-
tor peptide of PGC-1α bound to the receptor coactivator 
recruitment surface; it is not known if the presence of this 
peptide facilitates stabilization of the active conformation 
of estrogen-related receptor alpha in the crystals, or if the 
structure of the aporeceptor ligand-binding pocket would 
be more open in the absence of the PGC-1α peptide. The 
coactivator recruitment surface of estrogen-related receptor 
alpha formed from helices 3, 4, 5, and 12 is similar to that of 
estrogen receptor alpha. The PGC-1α peptide is anchored by 
Figure 7 Structures of the ligand-binding domains of estrogen receptor alpha and estrogen-related receptor alpha in complex with their ligands. 
Notes: Ribbon representations of the three-dimensional crystal structures of the ligand-binding domains of estrogen receptor alpha in complex with estradiol (a); DeS (b); 
4-hydroxy-tamoxifen, a high-affinity metabolite of tamoxifen (c); and raloxifene (d), and of estrogen-related receptor alpha in complex with a PGC-1α peptide (e); compound 
1a (f); and compound 29 (g) (A). Helices 1–11 of estrogen receptor alpha are colored pale pink and those of estrogen-related receptor alpha pink. The 12th helices are 
colored darker shades of pink and the short antiparallel beta sheets are colored yellow. The ligands, shown in stick view, and coactivator peptides, shown in a ribbon 
representation, are colored green if they increase activity of the receptor and red if they inhibit its activity. The helices are numbered and the four charged residues proposed 
initially to be critical for coregulator interaction are labeled. Ribbon representations of the ligand-binding pockets of estrogen receptor alpha in complex with estradiol and 
of estrogen-related receptor alpha in complex with a PGC-1α peptide are shown with estradiol shown in stick representation (B). The molecules are rotated to the right 
compared to the views shown in (A), with helix 11 to the front and helix 12 to the right of the structures. Much of helix 11 has been removed to allow better visualization of 
the occupancy of the ligand-binding pockets. The side chains of the four phenylalanine residues, Phe232, Phe286, Phe399, and Phe414, that are orientated towards the ligand-
binding pocket of estrogen-related receptor alpha and are thought to contribute to stabilization of its active conformation, and the equivalent residues of estrogen receptor 
alpha, Ala350, Phe404, Leu426, and Leu442, are indicated and labeled, and their side chains are shown in stick representation (top) or in space-filling mode (bottom). Helices 
are numbered and colored as in (A). Ribbon representations of the coactivator recruitment surfaces of estrogen receptor alpha in complex with DeS and a GRiP1 peptide, 
and of estrogen-related receptor alpha in complex with a PGC-1α peptide, are shown (C). The molecules are rotated slightly to the left compared to the views shown in (A) 
to allow better visualization of the hydrophobic cleft formed between helices 3, 4, 5, and 12. The helices are numbered and colored as in (A). The residues involved in the 
coactivator peptide interaction are shown in stick representation (top) and space-filling representation (bottom). Most have hydrophobic side chains and are colored light 
blue. The charged Lys and Glu residues that form charged capping interactions at either end of the coactivator peptide are colored blue and red, respectively. Conserved 
residues that were identified as being involved in interactions with the coactivator peptides in both structures and that are clearly visible in the figure are indicated. All images 
were created with PyMol Molecular Graphics Software (Schrödinger, Portland, OR, USA). 
Abbreviations: DeS, diethylstilbestrol; PGC, peroxisome proliferator-activated receptor gamma coactivator.
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canonical charge clamp interactions with Lys244 from helix 
3 and Glu416 from helix 12, and many of the conserved 
hydrophobic residues interact with the coactivator peptides 
in both structures (Figure 7C).74,75
The estrogen-related receptor alpha ligand-binding pocket 
is delineated by 22 amino acid residues, most of which have 
hydrophobic side chains. It is occluded by bulky hydrophobic 
side chains, in particular that of the phenylalanine Phe232 
from helix 3,75 which is an alanine in the other four recep-
tors, to create a cavity of only 100 Å3, which is substantially 
smaller than those of the estrogen receptor alpha (490 Å3) 
or beta (390 Å3) (Figure 7B). Removal of this hydropho-
bic side chain abolishes activity of the  aporeceptor. It is 
proposed that the presence in the ligand-binding pocket of 
Phe232 and other bulky hydrophobic side chains, notably 
Phe286 from the small beta sheet, Phe399 from helix 11, 
and Phe414 from helix 12, recapitulates the interactions 
provided by hydrophobic steroids in the estrogen receptors 
and allows the aporeceptor to hold an active conformation 
able to interact with coactivator proteins.75 Disruption of the 
interactions between Phe232, Phe286, Phe399, and Phe414 
destabilizes the active conformation of the estrogen-related 
aporeceptor alpha.
Interestingly, estrogen-related receptor alpha retains 
the charged Glu235 and Arg276, of which the equivalent 
residues in estrogen receptor alpha form a hydrogen bond 
network with the hydroxyl group on carbon 3 of the A ring 
of all three estrogens.  Estrogen-related receptor alpha retains 
also the polar His298 that forms a hydrogen bond with the 
hydroxyl group on carbon 17 of the D ring of estradiol and 
estriol. It is suggested, however, that insertion of an estrogen 
into the ligand-binding pocket of estrogen-related receptor 
alpha would cause such serious steric clashes, notably with 
the side chains of Phe232 and Phe399, that even the A ring 
would not be accommodated (Figure 7B).75
The occlusion of the estrogen-related receptor alpha 
ligand-binding pocket by bulky hydrophobic side chains 
indicates that the introduction of a molecule with more than 
four or five carbon atoms would necessitate a conformational 
change that would displace helix 12 from the coactivator 
surface.75 The estrogen-related receptor alpha does not 
bind estrogens or 4-hydroxytamoxifen, but does interact 
with the synthetic estrogen diethylstilbestrol to prevent 
the receptor interaction with SRC-1. Antagonist effects of 
 diethylstilboestrol on estrogen-related receptor alpha activity 
have been reported by some but not all authors.71,76 Modeling 
indicates that diethylstilbestrol would only be accommodated 
in the estrogen-related receptor alpha ligand-binding pocket 
if the side chains of Phe232 from helix 3 and Phe399 from 
helix 11 were to assume different conformations, and if 
Phe414 was removed from the hydrophobic cavity by dis-
placement of helix 12.29,30 That these conformational changes 
would disrupt the favorable cluster of phenylalanines Phe232, 
Phe286, Phe399, and Phe414, might indicate that the affin-
ity of diethyl stilboestrol for estrogen-related receptor alpha 
would be weak. Substitution of Phe232 with an alanine 
residue, which is found in the equivalent position in the 
other four members of the estrogen receptor family, allows 
4-hydroxytamoxifen to bind estrogen-related receptor alpha 
with a relatively high affinity of 4×10–8 M.77
Despite the steric constraints described above, several 
phytoestrogens: the flavone 6,3′,4′-trihydroxyflavone and 
the isoflavones genistein, daidzein, and biochanin A, have 
been reported to be agonists for estrogen-related receptor 
alpha activity.76 Phytoestrogens are produced by plants, 
have bactericidal and fungicidal activity, and represent 
the major natural exogenous sources of estrogenic com-
pounds. The results indicate that it is possible for a ligand 
to interact with estrogen-related receptor alpha to augment 
its activity.
Physiological functions of estrogen-
related receptor alpha
Discovery of estrogen-related receptor alpha immediately 
prompted questions of its physiological function: whether it 
overlapped with that of the estrogen receptor and if the recep-
tor had a role in breast cancer. Estrogen-related receptor alpha 
is expressed in the later stages of embryonic development 
and is abundant in heart, skeletal muscle, and the nervous 
system. The physiological role of estrogen-related receptor 
alpha, and of estrogen-related receptor gamma, is to act as 
an energy sensor to control cellular adaptation to energy 
demand and stress. To this end, estrogen-related receptor 
alpha is expressed at high levels in tissues with high energy 
demands, such as muscle and brown adipose tissue. Cells that 
do not express active estrogen-related receptor alpha cannot 
produce sufficient energy in times of peak demand.
Role of estrogen-related receptor  
alpha in metabolism
In adipose tissue, estrogen-related receptor alpha increases 
the differentiation of mesenchymal stem cells into adipocytes 
and hence enhances fat deposition. Further, estrogen-related 
receptor alpha has a role in the regulation of energy 
metabolism in adipocytes. It increases lipid uptake, fatty 
acid beta-oxidation, the tricarboxylic acid cycle, oxidative 
Cancer Management and Research 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
241
estrogen-related receptor α: a therapeutic target in breast cancer?
 phosphorylation, and mitochondrial biogenesis and  function. 
Effects of estrogen-related receptor alpha on metabolism 
extend to other tissues with high energy requirements, 
notably cardiomyocytes and macrophages. The importance 
of estrogen-related receptor alpha in metabolic regulation is 
emphasized by the demonstration that esrra-null mice have 
impaired fat absorption and metabolism and are relatively 
resistant to fat-induced obesity.78 These lean mice are unable 
to adapt to cold environments and develop cardiac contrac-
tile dysfunction. The cardiac hypertrophy induced by stress 
in esrra-null mice is caused by reduced ATP synthesis and 
reduced phosphocreatine storage.79
Role of estrogen-related receptor  
alpha in osteogenesis
Estrogen-related receptor alpha influences the differen-
tiation of myocytes, T-cells, intestinal epithelial cells, and 
osteoblasts. A report indicated that estrogen-related recep-
tor alpha has a role in bone development and metabolism 
during embryogenesis.80 Its messenger RNA is expressed in 
murine bone cells during bone formation by endochondral 
and intramembranous ossification and in primary human 
osteoblasts. Estrogen-related receptor alpha was found 
to affect transcription of an osteopontin gene promoter; 
osteopontin is an important constituent of the mineralized 
extracellular matrix of bones.80 In essra-null mice, absence 
of estrogen-related receptor alpha increased modestly osteo-
blast differentiation and cancellous bone mineral density, as 
well as mesenchymal cell differentiation into osteoblasts.81 
Further, estrogen-related receptor alpha was shown to 
decrease differentiation of human mesenchymal stem cells 
into osteoblasts, osteopontin expression, and mineral deposi-
tion, but to increase adipocyte differentiation.81 In a different 
strain of essra-null mice, female bones aged less compared 
to those of wild-type mice even after estrogen depletion and 
their marrow mesenchymal stem cells showed greater ability 
to differentiate into osteoblasts ex vivo.82 Thus estrogen-
related receptor alpha has a pivotal role in determination of 
mesenchymal stem cell fate and is implicated in inhibition 
of mineralization by osteoblasts.80–82
Genes induced by estrogen-related 
receptor alpha
Genomic studies indicate that estrogen-related receptor 
alpha regulates large numbers of genes involved in energy 
metabolism. Estrogen-related receptors interact with the pro-
moters of most mitochondrial and cellular genes that encode 
enzymes involved in the glycolytic pathway, the tricarboxylic 
acid cycle, and oxidative phosphorylation, and in nucleic acid, 
amino acid, lipid, and pyruvate synthesis. Estrogen-related 
receptor alpha is involved in the transcriptional regulation 
of genes required for mitochondrial biogenesis, the tricar-
boxylic acid cycle, oxidative phosphorylation, fatty acid 
oxidation, and lipid metabolism.83–85 For instance, estrogen-
related receptor alpha induces expression of NRF1, GAPα, 
and PPARα.86 The nuclear receptor coactivators PGC-1α, 
PGC-1β, and PPRC-1 are implicated in the regulation of 
these genes and in the autoregulation of the expression of 
estrogen-related receptor alpha. It has been suggested that 
the metabolic effects of estrogen-related receptor alpha are 
controlled by PGC-1α.85 PGC-1α is expressed at low basal 
levels but is induced by fasting and other metabolic stresses.83 
PGC-1β, a related coactivator, has similar functions, but its 
expression may not be regulated as acutely by variations in 
energy demand.84
Activation of estrogen-related  
receptor alpha
If the estrogen-related receptor alpha is fully functional in 
the absence of ligand, does this mean that it is constitutively 
active? Current thoughts are that its activity is regulated in 
two main ways (Figure 3B). First, its activation is limited by 
the intracellular concentrations of its coregulators. Rather 
than being regulated by interaction with a classic ligand with 
resultant stabilization of an active receptor conformation, 
the magnitude of estrogen-related receptor alpha activity is 
thought to be dependent largely on the presence of transcrip-
tional coactivators of transcription such as PGC-1α, PGC-1β 
and PPARβ, SRC-3 and PPGC183,87,88 or corepressors of 
transcription such as RIP140 and nuclear receptor corepres-
sor 1 (NCoR1).89,90 Whether or not the coactivators induce or 
stabilize the active conformation of estrogen-related receptor 
alpha is unknown. Certainly, the coregulators are essential 
for most estrogen-related receptor alpha activity and have 
been termed surrogate ligands. Induction of the expression 
of the coregulators by external metabolic stress activates 
estrogen-related receptor alpha.
Secondly, receptor activity is controlled by posttransla-
tional modification (Figure 3B), namely by phosphorylation 
initiated by the interaction of growth factors such as the IGFs 
and epidermal growth factors (EGFs) with their cognate 
receptors and consequent signal transduction. Recruitment 
of estrogen-related receptor alpha to the TFF1 promoter 
and resultant transcription are increased in the presence 
of EGF, possibly via phosphorylation of the DNA-binding 
domain.91 Activation of HER2 increases the transcriptional 
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activity of estrogen-related receptor alpha by phosphoryla-
tion at multiple residues, including in the carboxy-terminus.92 
In vitro analyses of the ability of estrogen-related receptor 
alpha to induce transcription from the TFF1 gene in breast 
cancer cells demonstrated that the induction is increased 
by activation of growth factor receptors including EGF 
receptor, HER2 and the type I IGF receptor.93 In addition, 
phosphorylation-dependent, amino-terminal SUMOylation 
reduces transcriptional activity of estrogen-related receptor 
alpha94 and acetylation by p300 coactivator-associated factor 
(PCAF) of four lysine resides in its DNA-binding domain 
modulates its activity.95
Role of the estrogen-related 
receptor alpha in breast cancer
Preclinical studies
The estrogen-related receptor alpha receptor has been pro-
mulgated as a prospective target for breast cancer therapy 
based in part on preclinical analyses. Knockdown of estrogen-
related receptor alpha mRNA in estrogen-responsive and 
estrogen-unresponsive breast cancer cells decreased their 
migratory potential, possibly by induction of WNT11 and 
vascular endothelial growth factor expression.96 Similarly, 
reduction of estrogen-related receptor alpha mRNA with 
miR-137 decreased the migratory and proliferative capacity 
of breast cancer cells.97 While proliferation in vitro was unaf-
fected, proliferation of xenografts of estrogen-unresponsive 
breast cancer cells was reduced after knockdown of estrogen-
related receptor alpha mRNA.98 Further, genetic deletion 
of esrra delayed tumor development in a mouse model of 
HER2-induced mammary tumorigenesis.99 The ability of 
estrogen-related receptor alpha to increase orthotopic tumor 
growth may be explained by its promotion of angiogenesis by 
induction of vascular endothelial growth factor.100 In appar-
ent contradiction, estrogen-related receptor alpha expression 
decreased the growth of osteolytic metastases in a mouse 
model of breast cancer, possibly via reduced osteolysis as 
a result of the induction of osteoprotegerin, which inhibits 
osteoclastogenesis.100
Tumor metabolism
The importance of estrogen-related receptor alpha in the 
control of cellular energy metabolism suggests that it may 
be involved in breast cancer cell metabolism.79 Estrogen-
related receptor alpha could facilitate glycolytic metabolism 
by tumor cells. Its relatively high expression in tumors 
with poorer prognosis, some of which manifest increased 
glucose uptake, which is associated with a more aggressive 
 phenotype,  supports this conjecture. In breast cancer cells, 
estrogen-related receptor alpha increases the expression of 
critical enzymes of the glycolytic pathway.98,101 Estrogen-re-
lated receptor alpha expression may also favor mitochondrial 
oxidative respiration in breast cancer cells through its regula-
tion of genes involved in mitochondrial oxidative function.86 
Breast cancer cells that had been selected for their ability to 
metastasize to the brain, expressed estrogen-related recep-
tor alpha, PGC-1α, PGC-1β, and estrogen-related receptor 
alpha-regulated genes involved in the tricarboxylic acid cycle, 
glycolysis, and oxidative phosphorylation pathways at higher 
levels than unselected cells.102 Activation of estrogen-related 
receptor alpha by overexpression of PGC-1α in breast cancer 
cells increases oxidative metabolism.103 The induction by 
estrogen-related receptor alpha of genes involved in lipid, 
amino acid, and nucleic acid synthesis, in glutaminolysis, and 
in regulation of the pentose phosphate pathway implicates 
the receptor in anabolic biosynthesis.98,101 Further, estrogen-
related receptor alpha may protect breast cancer cells against 
oxidative damage and production of reactive oxygen species 
by induction of detoxifying enzymes such as glutathione 
S-transferase MU-1 (GSTM1), liver glutaminase (GLS2), 
and superoxide dismutase 2 (SOD2).98,101
Translational studies
A decade ago, two clinical studies reported that estro-
gen-related receptor alpha is involved in breast cancer 
progression.104,105 Estrogen-related receptor alpha expres-
sion is inversely correlated with estrogen receptor and pro-
gesterone receptor expression but is associated positively 
with expression of HER2.104 The authors suggested that 
estrogen-related receptor alpha might be able to substitute 
for estrogen receptor if expression of the latter is lost, espe-
cially in HER2-positive or tamoxifen-resistant tumors.104 
Estrogen-related receptor alpha is detected in around 55% 
of human breast cancers by immunohistochemistry and its 
expression is associated with increased risk of recurrence and 
poor prognosis.105 Estrogen-related receptor alpha mRNA 
levels are similar or higher than estrogen receptor mRNA 
levels in approximately one-quarter of breast tumors and 
are highest in tumors in which functional estrogen receptor 
is absent.105 In this context, estrogen-related receptor alpha 
response elements often overlap those of estrogen receptor 
alpha, and both receptors affect the in vitro transcription of 
genes that encode lactoferrin, osteopontin, aromatase, and 
TFF1.67,68,70,71 Conversely, estrogen-related receptor alpha is 
reported to induce transcription of the HER2 gene, whereas 
the estrogen receptor represses the transcription of HER2 in 
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the presence of estrogen.99 Estrogen-related receptor alpha 
is not an independent biomarker of prognosis of breast can-
cer patients, but the concerted expression of a cohort of 86 
genes that are regulated by the receptor is associated with 
poor prognosis.98
Critical analysis of the potential 
for targeting the estrogen-related 
receptor alpha in breast cancer 
management
There has been considerable interest in the therapeutic 
potential of the activation or suppression of estrogen-related 
receptor alpha activity. The important role of estrogen-related 
receptor alpha in mitochondrial biogenesis and oxidative 
metabolism suggests that its activation could be an effective 
therapeutic intervention in diabetes or metabolic diseases. 
Although more controversial, the possibility of targeting 
estrogen-related receptor alpha activity in the treatment 
of osteoporosis has attracted attention. Importantly, in the 
context of this review, interest in the inhibition of estrogen-
related receptor alpha in medical oncology has focused on 
the treatment of breast cancer.
Phenex Pharmaceuticals AG (Ludwigshafen, Germany) 
was interested in the potential to treat cancer, osteoporosis, 
obesity, lipid and cardiovascular disorders, or conditions that 
affect fertility and reproductive health. GlaxoSmithKline 
(Brentford, UK) investigated estrogen-related receptor alpha 
activation for the treatment of metabolic disease. Merck & 
Co., Inc. (Whitehouse Station, NJ, USA) considered its inhi-
bition in the context of breast cancer and metabolic disorders. 
Novartis (Basel, Switzerland) invested in the possibility of 
targeting breast cancer, metabolic diseases, and osteoporosis. 
Johnson and Johnson (New  Brunswick, NJ, USA) considered 
the treatment of obesity and insulin-insensitive diabetes. 
The last two companies have published structures of their 
synthetic compounds bound to the receptor.106,107 The SRI 
International (Menlo Park, CA, USA) has a compound in 
clinical trial. Notably, medicinal chemists at the Guangzhou 
International Business Incubator (Guangzhou, People’s 
Republic of China) have reported the synthesis of several 
series of biologically active ligands of the estrogen-related 
receptor alpha.108
Potential drugs
Natural ligands of the estrogen-related receptor alpha have 
not been identified, and it is generally accepted that the 
aporeceptor is active. The crystal structure of Kallen et al 
indicates that the aporeceptor has an active conformation in 
the absence of bound ligand, that the ligand-binding pocket 
is too small to accommodate an estrogen-like ligand, and 
that introduction of such a ligand would disrupt the active 
conformation (Figure 7).75 The crystals of estrogen-related 
receptor alpha included a coactivator peptide from PGC-1α, 
and it is possible that the presence of this peptide and its 
interaction with the receptor induces or favors adoption of 
the active conformation by the receptor. The corollary is that 
it is possible that, in the absence of the PGC-1α coactivator 
peptide, helix 12 of the receptor may be more mobile than 
is suggested by the crystal structure, and the ligand-binding 
site more open and flexible and able to accommodate a 
ligand larger than might be predicted from examination of 
the crystal structure.
Agonists
Given the failure to identify natural ligands for the estrogen-
related receptor alpha and widespread acceptance that 
the receptor is fully active in its unliganded form, it was 
surprising to discover that natural phytoestrogens had ago-
nist activity for estrogen-related receptor alpha. In 2003, 
Suetsugi et al identified potential agonists76 by virtual 
ligand screening of a homology model of the estrogen-
related receptor alpha ligand-binding domain based on 
the crystal structure of estrogen-related receptor gamma 
ligand-binding domain.77 Four ligands, three isoflavones: 
genistein, daidzein, and biochanin A, and one flavone: 
6,3,4-trihydroxyflavone, all of which are present in legumes 
and various herbs, were  identified (Figure 8).76 The virtual 
screening indicated that estradiol, the synthetic estrogen 
diethylstilbestrol, and 4-hydroxytamoxifen do not bind. The 
authors demonstrated that genistein, daidzein, biochanin 
A, and 6,3,4-trihydroxyflavone increased estrogen-related 
receptor alpha transcriptional activity.76
Later, scientists at GlaxoSmithKline failed to identify 
agonists through random screening of their compound 
 collection. Subsequently, they synthesized molecules pre-
dicted to interact with the ligand-binding domain by struc-
ture-guided design based on the 2004 crystal structure of the 
estrogen-related receptor alpha,75 but were unable to demon-
strate agonist activity.109 Subsequently, Peng et al synthesized 
a series of pyrido[1,2-α]pyrimidin-4-ones with a view to 
producing more potent agonists of the estrogen-related recep-
tor alpha and confirmed the compounds’ ability to increase 
the transcriptional activity of the receptor (Figure 8).110 The 
compounds improved the uptake of glucose and fatty acids by 
muscle cells and have potential in the treatment of metabolic 
disease.110 Taken together, these data indicate that there are 
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Figure 8 Ligands of estrogen receptor alpha and estrogen-related receptor alpha. 
Notes: Outline structures of the estrogen receptor alpha (A) and estrogen-related receptor alpha (B) ligands are shown. The natural ligands of estrogen receptor alpha: 
estrone, estradiol, and estriol are outlined in pink. Synthetic ligands: diethylstilbestrol (DeS), tamoxifen and its metabolite 4-hydroxytamoxifen, raloxifene, and fulvestrant are 
uncolored (A). Phytoestrogens: genistein, daidzein and its metabolite equol, biochanin A, 6,3,4-trihydroxyflavone, and kaempferol are outlined in pale pink. Synthetic ligands: 
pyrido [1,2-α] pyrimidine-4-ones, XCT790, compound A, compound 1a, compound 29, troglitazone, AM251, compound 14n and SR16388 are uncolored (B). Names of the 
natural ligands and of other ligands that stimulate receptor activity are in green, and those of ligands that inhibit at least some receptor activity in red.
ligands whose interaction with the estrogen-related receptor 
alpha stabilizes the active conformation of the receptor and 
increases its transcriptional activity. These molecules or their 
derivatives have potential clinical utility for the treatment 
of metabolic diseases, including metabolic syndrome and 
diabetes.
inverse agonists
The demonstration that two organochlorine pesticides, toxa-
phene and chlordane, antagonize estrogen-related receptor 
alpha activity established the principle that the activity of 
the aporeceptor may be inhibited by a ligand.111 The dietary 
 flavonol kaempferol, which is present in tea, brassicas, 
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legumes, and some fruits, prevents interaction of estrogen-
 related receptor alpha with DNA response elements and 
hence its effects on transcription (Figure 8).112 Such com-
pounds are called reverse agonists or inverse agonists. Several 
groups have synthesized inverse agonists of estrogen-related 
receptor alpha and sought to demonstrate their therapeutic 
potential in preclinical models.
In 2004, Busch et al reported the first synthetic inverse 
agonists of estrogen-related receptor alpha.113 Their 
search was initiated by a high-throughput screen of their 
compound library followed by optimization of their lead 
structure to develop a potent, selective, and orally-available 
compound, (2E)-3-(4-([2,4-bis(trifluoromethyl)benzyl]
oxy)-3-methoxyphenyl)-2-cyano-N-[5-(trifluoromethyl)-1-
,3,4-thiadiazol-2-yl]acrylamide, or XCT790 (Figure 8).113 
Several other groups have studied the effects of XCT790 
on the biological activity of estrogen-related receptor alpha 
and established that XCT790 induces ubiquitin-dependent 
proteasomal degradation of estrogen-related receptor alpha.114 
XCT790 treatment was found to increase glucose uptake and 
mitochondrial production of reactive oxygen species and 
decrease mitochondrial mass and membrane potential.115–118 
The proliferation of estrogen-responsive and estrogen-
unresponsive breast cancer cells is inhibited by XCT790.119 
XCT790 prevents the induction in vitro by estrogen-related 
receptor alpha of the expression of genes whose expression 
in tumors is associated with poor patient prognosis.93
Chisamore et al searched for inverse agonists by examina-
tion of the ability of compounds to antagonize the interac-
tion between estrogen-related receptor alpha ligand-binding 
domain and the coactivator interaction domain of PGC-1α.120 
They identified a novel tricyclic antagonist, N-[(2Z)-3-(4,5-
dihydro-1,3-thiazol-2-yl)-1,3-thiazolidin-2-ylidene]-5H 
dibenzo[a,d][7]annulen-5-amine, or compound A, that binds 
estrogen-related receptor alpha with high affinity (Figure 8). 
The authors developed a homology model of estrogen-related 
receptor alpha in an antagonist conformation to explain the 
specificity of compound A. Subsequently, Chisamore et al 
demonstrated that compound A decreased expression of 
estrogen-related receptor alpha-responsive genes that encode 
TFF1, osteopontin, and aromatase.121 Estrogen-related recep-
tor alpha protein degradation is induced by compound A 
through the ubiquitin 26S proteasome pathway.121  Compound 
A was shown to inhibit the proliferation of estrogen-
 responsive and estrogen-unresponsive breast cancer cells and 
reduce their growth in xenograft models.122
The first structure of a cocrystal of a synthetic inverse 
agonist in complex with the estrogen-related receptor alpha 
ligand-binding domain was reported in 2007 by Kallen et al.106 
The authors produced cyclohexylmethyl-(1-p-tolyl-1H-indol-
3-ylmethyl)-amine, or compound 1a (Figure 8), by evolution 
of a lead compound identified through high-throughput 
screening. In the complex with compound 1a, part of the 
ligand fits into the ligand-binding pocket of estrogen-related 
receptor alpha and the aromatic side chains of Phe232 from 
helix 3, Phe399 from helix 11, and Phe414 from helix 12 do 
not cluster (Figure 7A). The remainder of compound 1a pro-
trudes from the ligand-binding pocket. The last turn of helix 11 
is unwound and the amino-terminus of helix 3 is in a different 
position than in the structure of the aporeceptor in complex 
with the coactivator peptide from PGC-1α. Helix 12 of the 
estrogen-related receptor alpha is not aligned in its agonist 
position but lies in the groove occupied by the coactivator 
peptide from PGC-1α in the cocrystal with the aporeceptor. 
This alignment of helix 12 is similar to the alignment of helix 
12 in the crystal structures of estrogen receptor alpha with the 
antiestrogens 4-hydroxytamoxifen and raloxifene. Interaction 
of coactivator LXXLL motif peptides with the coactivator 
recruitment surface is prevented, which may well account for 
the inverse agonistic effects of compound 1a.106
More recently, Patch et al used a high-throughput binding 
assay to identify unbiased ligands for estrogen-related receptor 
alpha.107 Compounds were tested for their ability to inhibit 
interaction with a coactivator peptide of SRC-2. Subsequent 
optimization produced 4-(4-[[(5R)-2,4-dioxo-1,3- thiazolidin-
5-yl]methyl]- 2-methoxyphenoxy)-3-(trifluoromethyl)
benzonitrile, or compound 29, as the most potent ligand 
(Figure 8). A cocrystal structure of the ligand-binding domain 
of estrogen-related receptor alpha with compound 29 revealed 
a covalent interaction between the ligand and the receptor that 
is known to be reversible.107 Helix 12 is aligned in a similar 
position to that found in the cocrystal with compound 1a 
adjacent to the hydrophobic cleft formed between helices 3, 
4, and 5, which means that helix 12 prevents interaction of 
coactivators with this receptor coactivator recruitment surface 
(Figure 7A). Interestingly, Patch et al demonstrated that com-
pound 29 was functionally active in metabolic animal models 
and proposed its development as a novel antidiabetic agent. 
Oral administration of compound 29 stabilized insulin and 
circulating triglyceride levels and improved insulin sensitivity 
but did not affect body weight in diet-induced murine models 
of obesity and in an overt diabetic rat model.107
Wang et al found that that the thiazolidinedione (RS)-5-
(4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]
benzyl)thiazolidine-2,4-dione, or troglitazone (Figure 8), 
which was marketed originally as an antidiabetic agent but 
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withdrawn due to liver toxicity, is an effective inverse agonist 
of estrogen-related receptor alpha.123 The troglitazone- receptor 
complex does not interact with the coactivators PGC-1α 
and PGC-1β, and troglitazone inhibits mitochondrial func-
tion. Mitochondrial mass was reduced and the expression of 
superoxide dismutases suppressed, which elevated reactive 
oxygen species production. The increase in reactive oxygen 
species in turn induced expression of the cell cycle inhibitor 
p21.123 Investigation of a pyrazole derivative, the cannabinoid 
1 receptor inverse antagonist biarylpyrazole compound 1-(2,4-
dichlorophenyl)-5-(4-iodophenyl)-4- methyl-N-1-piperidinyl-
1H-pyrazole-3-carboxamide, or AM251 (Figure 8), in 
cannabinoid 1 receptor-null cells identified estrogen-related 
receptor alpha as an alternative receptor.124 Interaction between 
AM251 and estrogen-related receptor alpha inhibited its tran-
scriptional activity and induced its proteolytic degradation. 
AM251 displaced diethylstilboestrol from the ligand-binding 
domain of recombinant estrogen-related receptor alpha. Sub-
sequent studies confirmed that AM251 effects are mediated by 
proteasomal degradation of nuclear estrogen-related receptor 
alpha.125 Downregulation of estrogen-related receptor alpha 
by AM251 or small interfering RNA led to increased mito-
chondria biogenesis and reduced mitochondrial membrane 
potential. These results indicate that the clinical analog of 
AM251, rimonabant, which is prescribed to decrease food 
intake, could exert its inhibitory effects against obesity, at 
least in part, through estrogen-related receptor alpha.
Most recently, Xu et al reported synthesis of a series of 
1-phenyl-4-benzoyl-1H-1,2,3-triazoles as novel suppressors 
of estrogen-related receptor alpha transcriptional activa-
tion.108 The most promising compound, 2-aminophenyl-(1-
(3-isopropylphenyl)-1H-1,2,3-triazol-4-yl)methanone, or 
compound 14n (Figure 8), reduced with an IC
50
 of 0.021 μM 
the transcriptional activation by estrogen-related receptor 
alpha as assessed in a cell-based reporter gene assay and 
decreased breast cancer cell migration and proliferation. 
Preliminary pharmacokinetic studies suggested that com-
pound 14n has a good pharmacokinetic profile, with an oral 
bioavailability of 71.8%.108
The synthetic inverse inhibitor of estrogen-related receptor 
alpha that has advanced furthest towards clinical application 
is (E)-3-Hydroxy-7α-methyl-21-[2′-(N,N,-dimethylamino)
ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene, or SR16388 
or TAS-108 (Figure 8).126,127 This novel steroidal compound 
was developed by SRI International for the treatment of breast, 
prostate, ovarian, and colon cancer in the hope that it would 
inhibit the effects of estrogen-related receptor alpha on energy 
 metabolism of tumor cells by inhibition of hypoxia-inducible 
factor 1-alpha and hence prevent tumor cell survival in hypoxic 
conditions by prevention of angiogenesis and induction of 
apoptosis.126,127 SR16388 also inhibits estrogen receptor alpha. 
Malignant cell growth in xenograft models is inhibited with 
an IC
50
 of around 0.2 μM and the inhibition is potentiated in 
the presence of microtubulin inhibitors such as paclitaxel or 
vincristine.127 Promulgated for treatment of tamoxifen-resistant 
breast cancer and bicalutamide-resistant prostate cancer, 
SR16388 has completed Phase I trials, as well as Phase II tri-
als for different tumor types. Benefits demonstrated in these 
studies include: antitumor efficacy in breast cancer patients 
who have relapsed while on treatment with an antiestrogen 
or an aromatase inhibitor; similar reduction in bone mineral 
density compared with aromatase inhibitors; no thickening of 
the endometrium; and a good overall safety profile. A Phase III 
trial of SR16388 in combination with a microtubulin inhibitor 
has been proposed.
inhibitors of protein interactions
The second most popular approach by which to inhibit 
the activity of estrogen-related receptor alpha is to prevent 
interaction between the receptor and the coactivators and 
corepressors that interact with the coactivator surface that lies 
between helices 3, 4, 5, and 12 in the active conformation of 
the receptor (Figure 7A and C).75 There are no prototype drugs 
reported, but the importance of these interactions in modulat-
ing the activity of the receptor is recognized.90,98,128 The success 
of the nutlins that disrupt interaction between p53 and MDM2 
demonstrates the feasibility of a strategy to disrupt interactions 
between two important intracellular proteins.
Repression of expression by microRNA 
A third possibility that has been mooted is to exploit the 
regulation of estrogen-related receptor alpha expression by 
the microRNA miR-137.97 This microRNA reduced expres-
sion of estrogen-related receptor alpha in breast cancer cells 
and consequently reduced breast cancer cell proliferation and 
migration.97 Therapeutic intervention with inhibitory RNAs 
is in its infancy, but the existence of this regulatory control 
of estrogen-related receptor alpha provides an alternative 
strategy for therapeutic intervention.
Phosphorylation
Another possible intervention with which to inhibit estrogen-
related receptor alpha activity would be a drug designed to 
inhibit the activity of the intracellular signal  transduction 
proteins responsible for activation of the receptor by 
 phosphorylation. Inhibitors that target the IGF and EGF 
pathways6,30 are likely to affect the transcriptional activity of 
the estrogen-related receptor alpha.93 Examples of these drugs 
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are figitumumab and lapatinib.30,35 An advantage of such a 
therapeutic approach would be that other tumor promotion 
signal transduction induced through the growth factor path-
way would be prevented.
Clinical setting
Drugs that target estrogen-related receptor alpha are most 
likely to be introduced initially for the treatment of patients 
with advanced breast cancer, most probably with palliative 
intent (Figure 2E). There is evidence that the estrogen-
related receptor alpha may be an effective target in estrogen-
dependent and estrogen-independent tumors. The dearth of 
effective noncytotoxic drugs for the treatment of patients 
with triple-negative breast tumors that lack expression of 
estrogen receptor, progesterone receptor, and HER2 means 
that these patients are more likely to be offered such novel 
therapy. In addition, there is evidence from early clinical trials 
of SR16388 that estrogen-related receptor alpha inhibitors 
are effective in patients who have relapsed after treatment 
with tamoxifen or an aromatase inhibitor. Such patients might 
benefit from estrogen-related receptor alpha inhibitors.
Evidence of clinical benefit from drugs that target 
estrogen-related receptor alpha in the palliative setting would 
indicate that they should be considered for adjuvant therapy 
in patients diagnosed with early triple-negative breast cancers 
(Figure 2C). It would be necessary to consider if drugs that 
target estrogen-related receptor alpha activity should be given 
in combination with cytotoxic therapies or as single agents. 
The decision might be influenced by patient prognosis.
Patient stratification
Increasingly, promulgation of new drugs is accompanied by 
consideration of which patients are most likely to receive clin-
ical benefit. While pharmaceutical companies might wish that 
their novel drug could benefit, for example, all breast cancer 
patients, they must recognize that it is better to demonstrate 
activity in a subgroup of patients than no significant effect in 
all patients. Analogous to the estrogen receptor alpha, patients 
in whom the estrogen-related receptor alpha is expressed at 
high levels in tumor cells might be more likely to receive 
benefit. Presence of high concentrations of the coactivators 
PGC-1α and PGC-1β may also indicate that the patient is 
more likely to benefit from drugs that target the dependence 
of tumor cells on the estrogen-related receptor alpha. It is 
 possible that assessment of the metabolic reliance of the tumor 
cells might select those most likely to benefit.  Measurement 
of genes whose expression is particularly closely dependent 
on the activity of the estrogen-related receptor alpha, for 
instance, those that encode aromatase or TFF1, or enzymes 
in the glycolytic pathway or enzymes involved in oxidative 
phosphorylation, might predict the dependence of the tumor 
cells on its transcriptional pathway.
Estrogen receptor alpha might be a biomarker that pre-
dicts lack of response to drugs that target estrogen-related 
receptor alpha activity because the presence of estrogen 
receptor alpha and the progesterone receptor indicate the 
importance of the estrogen-responsive transcriptional path-
way in the tumor cells. In addition, based on the evidence 
that the estrogen-related receptor alpha may inhibit estrogen 
receptor alpha activity, inhibition of the former might pro-
mote the activity of the latter and enhance the progression 
of the estrogen-dependent breast disease.70,129,130,131 Other 
evidence suggests that inhibition of estrogen-related receptor 
alpha might potentiate the effects of fulvestrant.114
Potential side effects
Consideration of the therapeutic potential of the estrogen-
related receptor alpha encompasses its effectiveness in target 
malignant cells and its effects in other cells and other tissues. 
Clearly, toxicity studies and early clinical trials will investigate 
these effects and potential side effects, and dose limitation 
work will determine the optimum therapeutic threshold.
Osteoporosis
The effects of interventions that target exclusively the 
estrogen-related receptor alpha are unknown. It is thought 
that estrogen-related receptor alpha increases adipocyte for-
mation at the expense of osteoblast formation and activity.81 
This bone inhibitory role is supported by the demonstration 
that, in estrogen-related receptor alpha-null mice, the bone 
mineral density does not reduce with age.82 The protective 
effect prevails during estrogen deficiency. The true effects 
of estrogen-related receptor alpha on osteogenesis in vivo 
in humans are particularly important given the widespread 
incidence of osteoporosis in many breast cancer patients, the 
drug-limiting side effects of pure antiestrogens and aromatase 
inhibitors on bone density, and the potential complications of 
treatment in patients who may have received bisphosphonates 
or their replacements. SRI International has reported that 
early trial data indicate that the effect of SR16388, which 
inhibits both estrogen receptor alpha and estrogen-related 
receptor alpha, on bone mineral density is comparable to that 
of aromatase inhibitors.
Metastasis
Most relevant studies of estrogen-related receptor alpha activ-
ity suggest that it promotes reduction of bone formation.81,82 
The bone is a favored site of breast cancer cell metastasis. 
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The possibility that an inhibitor of estrogen-related receptor 
alpha activity might strengthen bone structure suggests that 
such a drug might, as a consequence, militate against the 
establishment of clinically significant metastatic deposits of 
breast cancer secondary tumors in bones. Such an activity 
would be desirable in the treatment of advanced breast cancer 
and could augment the effects of bisphosphonates. Evidence 
from a preclinical mouse model of bone metastasis contradicts 
this supposition; overexpression of estrogen-related recep-
tor alpha in the tumor cells reduced formation of osteolytic 
lesions. The corollary would be that inhibition of estrogen-
related receptor alpha activity might promote formation of 
bone metastases.100
Metabolism
Many of the inverse agonists of the estrogen-related recep-
tor alpha have been produced with the aim of managing 
metabolic diseases. Consideration must be given to the 
potential of detrimental side effects of oncological inter-
vention via estrogen-related receptor alpha on metabolic 
control in normal tissues with high energy requirements, 
such as skeletal muscle, heart, and kidney. There is concern 
that the decrease in PGC-1α and PGC-1β in the skeletal 
muscle of patients with diabetes and obesity would mean 
that inhibition of estrogen-related receptor alpha activity 
could be particularly detrimental in diabetic or obese breast 
cancer patients.132
Another consideration is that esrra-null mice exhibit 
cardiac hypertrophy.79 It would be important to consider 
potential detrimental effects of drugs that target estrogen-
related receptor activity on patients with underlying heart 
conditions, including cardiomyopathy. Combined treatment 
with drugs associated with heart damage, such as anthracy-
clines and trastuzumab, might be contraindicated.
Cachexia
A major concern is that estrogen-related receptor alpha 
inhibition would be catastrophic for patients with established 
cachexia or would exacerbate its development. Poorly under-
stood, cachexia is a major cause of morbidity and contributor 
to mortality in patients with advanced breast cancer. Cachexic 
patients have extensive muscle atrophy and fatigue, as well 
as severe weight loss associated with impaired metabolic 
function and nutrient sensing ability. The possibility that this 
condition might be worsened or hastened in breast cancer 
patients by drugs that inhibit estrogen-related receptor alpha 
activity is a major concern and should be a focus of any early 
clinical trials that involve dose escalation of the drugs.
Conclusion
Estrogen-related receptor alpha is an attractive target in breast 
cancer patients, in particular, in those for whom there are 
limited therapeutic options in either the palliative or adjuvant 
clinical setting. Several compounds that have inverse agonist 
activity for the receptor have been developed, and some have 
been shown to have high affinity and good oral availability 
and to interact with the ligand-binding domain to destabilize 
the active conformation and inhibit the transcriptional activity 
of the receptor. Preclinical studies suggest that inhibitors of its 
activity prevent breast cancer cell migration in vitro and prolif-
eration in vivo in mouse models. The possibility that they might 
enhance metastasis to the bone warrants further  investigation. 
The pivotal role of estrogen-related receptor alpha in energy 
metabolism suggests that its inhibition might target the high 
metabolism characteristic of many tumor cells.
Being an attractive target is a long way from introduction 
into routine clinical practice. Important areas of investigation 
include identification of valid biomarkers of dependence upon 
estrogen-related receptor alpha transcriptional activity and 
potential response to therapeutic intervention.  Successful 
identification of such biomarkers would ensure effective 
patient stratification and that only those with a high prob-
ability of benefit would receive treatment. The important 
roles of estrogen-related receptor alpha in energy metabolism 
and bone formation mean that inhibition of its effects in 
tissues with high energy requirements and in bone must be 
considered. Further, effects of inhibition of estrogen-related 
receptor alpha activity in those with metabolic disorders or 
diabetes, many of whom will develop breast cancer,6 will 
require careful investigation.
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